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Introduction 
Rising Stars: Recognizing Important New 
Voices in Law, Medicine, Science & 
Technology 
Michele B. Goodwin* 
In this special issue, important new voices in law, 
medicine, science, and technology comment on critical issues of 
national and international significance. They are the rising 
stars, applying sophisticated, interdisciplinary approaches to 
important policy matters that consume our courts, legislatures, 
and imaginations. The scholars participating in our invitation 
only special issue are among the most talented junior scholars 
in the academy 
Their collective works on privacy, reproductive technology, 
global health, the rise and challenges of contemporary 
biotechnologies, and what these issues mean for important 
stakeholders: the public, government, and business, offer 
refreshing, nuanced analytical probes into murky arenas, 
which are made all the more complicated by biotechnologies 
outpacing of the development of laws to regulate or harness 
their reach. The scholars participating in this important project 
for the Minnesota Journal of Law, Science & Technology were 
not given a specific charge. Rather, they were provided open 
canvasses and encouraged to paint in broad, open strokes. 
Their art provides revelatory insights with shared and often 
cautionary themes. 
Collectively, their wisdom reminds us about the 
importance of foundational values across the multiple spheres 
of biotechnology and its engagement in our lives, whether 
through assisted reproduction—its risks, challenges, and 
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rewards—or in the regulation and monitoring of science and 
those who conduct it, lest patients and the most vulnerable 
become the unwitting victims of biological mining and genetic 
exploitation. 
An interesting thematic link between their works is the 
cautionary note about unbridled technology and the importance 
of rules of law and the roles of law. Unlike their predecessors’ 
generations, these scholars observe that sophisticated 
biomedical technologies are more accessible to a broader group 
of citizens than ever before. But with accessibility come 
economic, political, and social realities, pressures, and 
responsibilities, particularly when the subjects of the 
technology are people, and the building blocks of life or 
reproductive technology are intimately associated with their 
bodies. These scholars predict a bright future for technology, 
but responsibly urge a critical exploration of the darker, 
murkier contours, where human exploitation, greed, 
incompetence, and lack of deference to the rules of law expose 
the vulnerabilities of law, science and modern technology. 
Readers will note the subtle, but evidenced themes relating 
to the challenges of biotechnology and risk in a global age; the 
call for recalibrating what disclosures should be demanded in 
an era where biotechnological advancements can at times 
incentivize unethical conduct that exploits the vulnerable, and 
the challenge in defining personhood and biology as the 
technological state and the products it produces has morphed. 
And in that evolution, biologics can have synthetic twins and 
companies can be persons. 
Scholars participating in this special issue observe that we 
live in a global community with increasingly narrow, rather 
than thick borders. They note that science all the more breaks 
down these barriers, but so do diseases and illnesses. James 
Hodge, for example, reminds us of the pitfalls when 
international collaboration and cooperation fails. 
In “Global Legal Triage in Response to the 2009 H1N1 
Outbreak,” Hodge reminds us that the disparate response to 
the virus that threatened possible international devastation 
was incoherent and incongruent at best. Despite WHO 
guidelines, “proven public health interventions were negated,” 
and as a result, “human rights abuses arose,” compounded by 
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the spread of the influenza and devastating economic impacts.1 
Hodge highlights a new era in law and science, where borders 
are permeable and not static, solid, and impenetrable. 
In this new era, where the luxury of international travel is 
frequent and afforded by more people, the probability of 
spreading viruses increases. The danger is that communicable 
diseases do not recognize borders and customs. How to combat 
that? Hodge emphasizes that with the luxury of travel come 
certain governmental challenges and responsibilities. For this 
reason, he warns that tepid response to international protocols 
to prevent the spread of deadly viruses will likely lead to 
economic and health disasters. His intuition is yet to be fully 
tested, but ample evidence from the spread of H1N1 helps to 
bolster his claim. 
At the intersection of technology and law collisions occur, 
and far too often race and gender operate at those locations.2 
Such was the case of Henrietta Lacks and the exploitation of 
her cell line. Largely forgotten or overlooked in the annals of 
medicine, Lacks’ story was first visited by journalist and 
author, Harriet Washington, in articles and her award winning 
work, Medical Apartheid: The Dark History of Medical 
Experimentation on Black Americans from Colonial Times to 
the Present. More recently, Rebecca Skloot takes up the charge 
to resurrect Lacks’ important contributions to science, in The 
Immortal Life of Henrietta Lacks, and Gail Javitt interrogates 
that work and reflects on the rule of law and respect for 
participants in tissue-based research. Javitt’s observations are 
part of this special issue. 
Javitt notes that in few cases has there been one to “single-
handedly” offer a “scientific paradigm shift.”3 But that 
paradigm shift, and the underlying motivations for the use of 
Ms. Lacks’ cell line, and the misinformation and lack of 
information provided to Lacks and her family paints a dark 
picture on the complicated canvass of American scientific 
history. At a time when African Americans were refused 
services at many hospitals across the United States, 
                                                          
 1. James G. Hodge, Global Legal Triage in Response to the 2009 H1N1 
Outbreak, 11 MINN. J. L. SCI. & TECH. 599, 627 (2010). 
 2. See e.g., Michele Goodwin and Song Richardson, Patient Negligence, 
72 DUKE J. OF L. & CONTEMPORARY PROBLEMS 223 (2010). 
 3. Gail Javitt, Why Not Take All of Me? Reflections on The Immortal Life 
of Henrietta Lacks and the Status of Participants in Research Using Human 
Specimens, 11 MINN. J. L. SCI. & TECH. 713, 713 (2010). 
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researchers discovered a treasure trove in her cell line that 
would change the manner in which pharmaceutical 
developments occur and how biological research is conducted 
for decades to come. Scientific researchers’ failure to provide a 
meaningful disclosure to Lacks’ family and obtain appropriate 
consent has caused a revisit of her case. 
Lacks’ valuable cell-line serves as the base of numerous 
life-saving vaccines and other treatments. But to tell Ms. Lacks’ 
story absent of the context of her times, and her status is to 
ignore the conditions under which scientific research becomes 
captive to coercion, exploitation and greed. Javitt, like her 
colleagues in this special issue, sketches a cautionary portrait 
of scientific research involving human subjects and their 
tissues. She argues that the “use of cells and tissues for 
research brings with it myriad legal and ethical questions.”4 
For example, to whom does the proprietary interest belong? 
Should ownership of a cell-line belong to anyone at all or be 
part of a public commons? 
 Javitt points out that important social and legal 
consequences result no matter how the questions are answered. 
More importantly is that the questions are answered, and that 
patient autonomy and dignity are honored and respected 
legally, medically, and ethically in medical tissue research. At 
the heart of her article are a set of urgent questions, including 
an inquiry as to what should govern “the voluntary provision of 
tissues by patient groups to researchers solely for the purpose 
of identifying the cause of their disease . . . .”5 Recent court 
cases make similar inquiries.6 Unfortunately, as Javitt notes, 
the judicial treatment of these issues is often mired in 
formalism, “in the service of what sometimes appear to be 
preordained policy goals.”7 For Javitt policy questions 
regarding the dignified use of human tissue for research 
purposes cannot be answered in isolation, but rather, must 
engage the public if trust is to be gained. As important, she 
offers that “new federal legislation that establishes 
prospectively clear, uniform terms of engagement between the 
three parties to the tissue research enterprise,” will be needed. 
                                                          
 4. Id. at 714. 
 5. Id. at  714. 
 6. See Michele Goodwin, Formalism and the Legal Status of Body Parts 
26 U. CHI. LEGAL F. 317, 317–88 (2005). 
 7. Javitt, supra note 3, at 715. 
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In synergistic fashion, Anne Drapkin Lyerly, also promotes 
the use of law to temper the excesses of innovative 
technologies. In Marking the Fine Line: Ethics and the 
Regulation of Innovative Technologies in Human Reproduction, 
Lyerly argues that, “far less attention has been directed at the 
regulation of research—of oversight for the process of moving 
from bench to bedside, innovation to practice,” of assisted 
reproductive technologies. Like Javitt, Lyerly observes the 
importance of critiquing law and status in context. In this case, 
the author turns her attention to mothers, their offspring, and 
the lack regulation in the field of assisted reproductive 
technology (ART). 
Lyerly unpacks a view of assisted reproductive technology 
overlooked in the media accounts of Nadya Suleman, the 
California mother that gave birth to octuplets after aggressive 
hormone therapies and the implantation of multiple embryos, 
or the case of Kate Gosselin, the celebrity-mother of eight. 
Rather, Lyerly’s pragmatic study of the ethics and regulations 
of ART is concerned “about [the] safe and ethical provision of 
reproductive medicine in the 21st century,” and with that, “the 
role of regulation of this process.”8 
Animating Lyerly’s concern in this issue, are health and 
safety considerations for the babies born from ART. When ART 
is more experiment than practice, vulnerable, less-informed 
patients, may become the unwitting subjects of scientific 
research. Lyerly draws readers’ attention to intracytoplasmic 
sperm injection (ICSI), a special reproductive technique that 
remains at the center of some controversy. 
Lyerly’s provocative work attempts to “pry apart” 
reproductive innovations that deserve greater legal scrutiny. 
She argues that while “new techniques may provide relief of 
the suffering caused by infertility and the birth of children with 
preventable disabilities,” such relief has also “ushered in 
problems with its progress.”9 Lyerly’s intuition that innovation 
is at times blurred with experimentation, serves as an 
important intellectual guidepost for scholars and policy-makers 
concerned about promoting biotechnology, while also protecting 
the public from harm. 
                                                          
 8. Anne Drapkin Lyerly, Marking the Fine Line: Ethics and the 
Regulation of Innovative Technologies in Human Reproduction, 11 MINN. J. L. 
SCI. & TECH. 685, 687 (2010). 
 9. Id. at 712. 
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In matters of technology, these rising stars emphasize the 
importance of access to information and researcher disclosure, 
as an important component of the legal and ethical monitoring 
processes. This important theme is picked up in Vardit 
Ravitsky’s informative article, “Knowing Where You Came 
From”: The Rights of Donor-Conceived Individuals and the 
Meaning of Genetic Relatedness.” Such thematic threads also 
appear in Braverman’s article, also published in this issue. 
Ravitsky’s article adds her voice to the growing chorus 
interrogating what disclosure means in the context of donor-
assisted births. Should children have a right to know their 
genetic parents? The normative questions driving her project 
emerge at multiple technological intersections: the use of 
technology to conceive, the use of third parties in that process, 
and social networking. At that unique intersection, young 
adults are driven to find answers to their genetic mysteries. 
Ravitsky suggests that part of what compels this desire “to 
know” is the psychological distress experienced in “not 
knowing.” For this reason, many donor-conceived teenagers and 
adults have taken on the charge to learn their origins. 
But the legal and ethical issues arising from the desire to 
know are not well-settled—if at all. Indeed, as Ravitsky 
suggests, “most fertility experts did not anticipate this 
outcome. They focused on their patients, helping them create 
the families they desired while perceiving the donor as a mere 
means in the process.”10 Thus, the interests, rights, and 
entitlements of donor-conceived offspring were largely ignored, 
not only by doctors and lawyers in the ART fields, but also the 
coordinating parents. Neither did state or federal legislatures 
enter this fray to help define the contours of privacy rights in 
the ART domain. 
Further complicating this space are the conflicting 
information disclosure interests between ART parents, genetic 
parents, and their mutual offspring. A child might want to 
know her genetic heritage, but ART and genetic parents may 
desire constraint—and for differing reasons. As Ravitsky 
rightly notes, at least in the cases of genetic parents, the 
“trend” to avoid disclosure, “was maintained because most 
                                                          
 10. Vardit Ravitsky, “Knowing Where You Come From”: The Rights of 
Donor-Conceived Individuals and the Meaning of Genetic Relatedness, 11 
MINN. J. L. SCI. & TECH. 665, 665 (2010). 
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donors wish to remain anonymous and have no intention of 
establishing a relationship with offspring, and most parents 
choose to keep the circumstances of conception secret.”11 
However, in an era where the interests of donor-conceived 
children have come to the forefront, prospective ART parents 
and the service providers they use are confronted with pressing 
questions (and very active internet campaigns) about identity 
disclosure. And the underlying motivations for urging a better 
disclosure regime vary from medical, psychological, and genetic 
concerns to a desire to avoid mistaken family building among 
individuals who might be genetic siblings or cousins. 
In the United States, donor identity is not regulated by 
state or federal law. Indeed, in most countries, the norm 
remains to protect donor anonymity, despite the fact that, 
“donor identity is gathering momentum as a growing number of 
countries are adopting laws and regulations banning 
anonymity.”12 For Ravitsky the important issue at hand is how 
these debates are framed and what is at stake in “knowing.” 
The effort is to avoid conflating all interests in ART disclosure 
as being equal or mutual, which are important lessons in law, 
science and medicine. 
Identity animates a third theme in this special issue 
devoted to rising stars in law, science, medicine, and 
technology. In a final thematic forage, both Andrea Matwyshyn 
and Andrew Torrance urge the reconsideration of what the 
biological means in an expanding biotechnological era. In a 
brilliantly written article, “Corporate Cyborgs and Technology 
Risks,” Matwyshyn contemplates a rising future where 
corporations increasingly take ownership of a personhood 
identity, but are in fact less human than ever before. Her work 
is not one of science fiction, but a critical analysis about 
corporate identity and the roles of law in promoting and 
harnessing technology. 
 She writes, “the law has long treated corporations as 
persons with rights, and it continues to expand this 
treatment.”13 And with this, she evaluates that the “practical 
differentiation between human persons and corporate persons 
grows tenuous in many respects to the outside world,” despite 
                                                          
 11. Id. at 665–66. 
 12. Id. at 666. 
 13. Andrea M. Matwyshyn, Corporate Cyborgs and Technology Risks, 11 
MINN. J. L. SCI. & TECH. 573, 573 (2010). 
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the fact that corporations are becoming “less human.” In an era 
of corporate downsizing, corporations rely less on human power 
and brain trust than information systems with external 
humanization components. To Matwyshyn this morphing of 
“human-machine identity” risks a broad acceptance of 
“overzealous technology adoption” without critical auditing, 
monitoring, and where necessary disciplinary protocols. 
Matwyshyn argues that these incongruent forces—a more 
deeply humanized status of corporate identity married to far 
less human interaction demands new legal considerations. She 
argues that this contradiction and “shift has carried with it 
technology driven risks to both individual entities and the 
economy as a whole.”14 Drawing from the securities industry as 
a case study of “cyborg” transformations, she critically 
examines the landmines that plagued securities markets in the 
1960s and 70s and the crisis point at which the SEC 
intervened. In forecasting a similar future for companies at the 
forefront of various technologies, she urges an ex ante response. 
The recent Gulf oil spill and the lack of precautionary measures 
to contain that devastation adds urgency to her analysis. 
Matwyshyn calls for an information accountability regime. 
She argues quite persuasively for internal and external 
corporate oversight “that more effectively blends” multiple legal 
regimes. Her project is ambitious, calling for the cross 
fertilization of corporate, securities, contract, intellectual 
property, tort and criminal law regimes to proactively protect 
our biotechnological futures and possibilities. Matwyshyn’s 
project provides a platform for new policy leadership on 
corporate accountability in a biotech age. 
 Most fitting, perhaps, is to conclude these introductory 
comments with a reflection on our final Rising Stars author, 
Andrew Torrance, and his contribution to this special issue: 
“Synthesizing Law For Synthetic Biology.” Torrance’s work 
epitomizes scholarship at the intersections of medicine, law, 
science, and technology, empirically and theoretically. His 
contribution to this issue builds on a nuanced and developing 
body of work that aims to effect paradigm shifts in biological 
sciences. Torrance, like Matwyshyn, hopes to incorporate 
standardizations and innovative monitoring and auditing 
mechanisms into the biological sciences. Both scholars attempt 
                                                          
 14. Id. 
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to borrow from domains that might offer contoured and tested 
approaches to counteract actual, perceived, and possible 
unbridled and unregulated technologies. 
Torrance takes up the case of synthetic biologics, such as 
synthetic DNA, with a concern about the ways in which a 
perceived ethos of openness in the industries that create these 
products could easily give way to less democracy and openness 
in the field. He points to the proprietary restrictions resulting 
from “closed” intellectual property as an example of legal risk 
and uncertainty. The challenge of course for those like Torrance 
who might wish this technology to be “open” to others is that 
synthetic forms are not “natural.” By definition as he concedes, 
“synthetic DNA sequences are likely more easily patentable 
and copyrightable than are DNA sequences derived from 
natural sources.”15 Torrance ultimately comes to the conclusion 
that runs through this special issue: collaboration, cooperation, 
and new legal frameworks must be developed to govern the 
legal relationships between biotech developers and the 
contributors and users they serve. 
CONCLUSION 
In deciding to host a special issue dedicated to the 
scholarship of “rising stars” my colleagues and I reflected on 
the importance and value of elevating voices that deserve a 
platform. These authors contribute to a broad and rich 
literature at the intersections of law, medicine, science, and 
technology. Their insights illuminate gaps in current legal 
regulation of biotechnologies, and yet offer creative, innovative 
frameworks for addressing 21st century challenges at the heart 
of law and science. 
Their works remind us that at the important intersection 
of law, science, and technological pioneering, social 
responsibility and accountability to the public must not be lost 
or bartered away. And with scientific achievements come 
responsibilities—sometimes unanticipated. These scholars’ 
nuanced approaches to challenging issues at the intersections 
will provide for an enriched and engaging dialogue for years to 
come. 
 
                                                          
 15. Andrew W. Torrance, Synthesizing Law for Synthetic Biology, 11 
MINN. J. L. SCI. & TECH. 629, 664 (2010). 
